Giles Dixon, Samuel Hague, Sarah Mulholland, Huzaifa Adamali, Aye Myat Noe Khin, Hannah Thould, Roisin Connon, Paul Minnis, Eoin Murtagh, Fasihul Khan, Sameen Toor, Alexandra Lawrence, Marium Naqvi, Alex West, Robina K Coker, Katie Ward, Leda Yazbeck, Simon Hart, Theresa Garfoot, Kate Newman, Pilar Rivera-Ortega, Lachlan Stranks, Paul Beirne, Jessica Bradley, Catherine Rowan, Sarah Agnew, Mahin Ahmad, Lisa G Spencer, Joshua Aigbirior, Ahmed Fahim, Andrew M Wilson, Elizabeth Butcher, Sy Giin Chong, Gauri Saini, Sabrina Zulfikar, Felix Chua, Peter M George, Maria Kokosi, Vasileios Kouranos, Philip Molyneaux, Elisabetta Renzoni, Benedetta Vitri, Athol U Wells, Lisa M Nicol, Stephen Bianchi, Raman Kular, HuaJian Liu, Alexander John, Sarah Barth, Melissa Wickremasinghe, Ian A Forrest, Ian Grimes, A John Simpson, Sophie V Fletcher, Mark G Jones, Emma Kinsella, Jennifer Naftel, Nicola Wood, Jodie Chalmers, Anjali Crawshaw, Louise E Crowley, Davinder Dosanjh, Christopher C Huntley, Gareth I Walters, Timothy Gatheral, Catherine Plum, Shiva Bikmalla, Raja Muthusami, Helen Stone, Jonathan C L Rodrigues, Krasimira Tsaneva-Atanasova, Chris J Scotton, Michael A Gibbons, Shaney L Barratt
BACKGROUND: Nintedanib slows progression of lung function decline in patients with progressive fibrosing (PF) interstitial lung disease (ILD) and was recommended for this indication within the United Kingdom (UK) National Health Service in Scotland in June 2021 and in England, Wales and Northern Ireland in November 2021. To date, there has been no national evaluation of the use of nintedanib for PF-ILD in a real-world setting. METHODS: 26 UK centres were invited to take part in a national service evaluation between 17 November 2021 and 30 September 2022...
January 2024: ERJ Open Research